Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Express Scripts
Moodys
Harvard Business School
AstraZeneca
Medtronic
Merck

Last Updated: December 13, 2019

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 022127

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

NDA 022127 describes RENVELA, which is a drug marketed by Genzyme and Sanofi and is included in two NDAs. It is available from two suppliers. There are two patents protecting this drug and two Paragraph IV challenges. Additional details are available on the RENVELA profile page.

The generic ingredient in RENVELA is sevelamer carbonate. There are thirty-two drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the sevelamer carbonate profile page.
Summary for 022127
Tradename:RENVELA
Applicant:Sanofi
Ingredient:sevelamer carbonate
Patents:1
Formulation / Manufacturing:see details
Pharmacology for NDA: 022127
Mechanism of ActionPhosphate Chelating Activity
Suppliers and Packaging for NDA: 022127
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
RENVELA sevelamer carbonate TABLET;ORAL 022127 NDA AUTHORIZED GENERIC Winthrop U.S. 0955-1050 0955-1050-27 270 TABLET, FILM COATED in 1 BOTTLE (0955-1050-27)
RENVELA sevelamer carbonate TABLET;ORAL 022127 NDA Genzyme Corporation 58468-0130 58468-0130-1 270 TABLET, FILM COATED in 1 BOTTLE (58468-0130-1)
Paragraph IV (Patent) Challenges for 022127
Tradename Dosage Ingredient NDA Submissiondate
RENVELA TABLET;ORAL sevelamer carbonate 022127 2008-12-04

Profile for product number 001

Active Rx/OTC/Discontinued:RXDosage:TABLET;ORALStrength800MG
Approval Date:Oct 19, 2007TE:ABRLD:Yes
Regulatory Exclusivity Expiration:Nov 25, 2019
Regulatory Exclusivity Use:NEW PATIENT POPULATION
Patent:  Start TrialPatent Expiration:Oct 27, 2025Product Flag?YSubstance Flag?Delist Request?

Expired US Patents for NDA 022127

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007   Start Trial   Start Trial
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007   Start Trial   Start Trial
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007   Start Trial   Start Trial
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007   Start Trial   Start Trial
Sanofi RENVELA sevelamer carbonate TABLET;ORAL 022127-001 Oct 19, 2007   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
McKesson
Harvard Business School
Dow
Colorcon
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.